Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out.
ART
Diagnosis
Diagnóstico
HIV/AIDS
Implementation challenges
Pathogenesis
Patogénesis
Resource-limited settings
Retos en implementación
Situaciones de recursos limitados
TARV
Tratamiento
Treatment
Tuberculosis
VIH/SIDA
Journal
Archivos de bronconeumologia
ISSN: 1579-2129
Titre abrégé: Arch Bronconeumol
Pays: Spain
ID NLM: 0354720
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
24
07
2019
accepted:
02
11
2019
entrez:
4
4
2022
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
ppublish
Résumé
Despite wide antiretroviral scale-up during the past two decades resulting in declining new infections and mortality globally, HIV-associated tuberculosis remains as a major public health concern. Tuberculosis is the leading HIV-associated opportunistic infection and the main cause of death globally and, particularly, in resource-limited settings. Several challenges exist regarding diagnosis, global implementation of latent tuberculosis treatment, management of active tuberculosis, delivery of optimal patient-centered TB and HIV prevention and care in high burden countries. In this article we review the advances on pathogenesis, diagnosis, and treatment after nearly two decades of global roll-out of antiretroviral therapy and discuss the current challenges for the global control of tuberculosis-HIV co-infection.
Identifiants
pubmed: 35373756
pii: S1579-2129(20)30151-8
doi: 10.1016/j.arbr.2019.11.013
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
446-454Informations de copyright
Copyright © 2020. Published by Elsevier España, S.L.U.